Financial News
Articles published by Olema Oncology
Olema Oncology to Participate in Canaccord Genuity 2024 Horizons in Oncology Virtual Conference
April 08, 2024
From Olema Oncology
Via GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
March 11, 2024
From Olema Oncology
Via GlobeNewswire
Tickers
OLMA
Olema Oncology to Participate in Upcoming Investor Conferences
February 06, 2024
From Olema Oncology
Via GlobeNewswire
Tickers
OLMA
Olema Oncology Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate
January 08, 2024
From Olema Oncology
Via GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 07, 2023
From Olema Oncology
Via GlobeNewswire
Tickers
OLMA
Olema Oncology Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant
October 22, 2023
From Olema Oncology
Via GlobeNewswire
Tickers
OLMA
Olema Oncology Appoints Oncology Biotech Executive Scott Garland to Board of Directors
October 17, 2023
From Olema Oncology
Via GlobeNewswire
Tickers
OLMA
Olema Oncology Announces Phase 2 Monotherapy Clinical Results to be Presented at the 2023 ESMO Congress
October 16, 2023
From Olema Oncology
Via GlobeNewswire
Tickers
OLMA
Olema Oncology to Participate in Upcoming Investor Conferences
September 06, 2023
From Olema Oncology
Via GlobeNewswire
Tickers
OLMA
Olema Oncology Announces Combined Financing for Up to $180 Million
September 05, 2023
From Olema Oncology
Via GlobeNewswire
Tickers
OLMA
Olema Oncology Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 08, 2023
From Olema Oncology
Via GlobeNewswire
Tickers
OLMA
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.